Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cidara Therapeutics Inc CDTX

Healthcare Biotechnology
Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak... see more

Recent & Breaking News (NDAQ:CDTX)

Cidara Therapeutics Provides Update on REZZAYO(TM) (rezafungin for injection)

GlobeNewswire July 31, 2023

Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program

GlobeNewswire July 20, 2023

Cidara Therapeutics Added to Russell Microcap® Index

GlobeNewswire June 26, 2023

Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B

GlobeNewswire June 22, 2023

Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit

GlobeNewswire June 20, 2023

Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit

GlobeNewswire June 13, 2023

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

GlobeNewswire May 11, 2023

Cidara Therapeutics Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388 at the 7th International Society for Influenza and Other Respiratory Virus Diseases Conference

GlobeNewswire May 3, 2023

Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO(TM)

GlobeNewswire April 24, 2023

Cidara Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire March 31, 2023

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire March 23, 2023

Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO(TM) (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis

Business Wire March 22, 2023

Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO(TM) (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis

GlobeNewswire March 22, 2023

Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress

GlobeNewswire March 7, 2023

Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares in Public Offering of Common Stock

GlobeNewswire March 7, 2023

Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock

GlobeNewswire March 3, 2023

Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock

GlobeNewswire March 2, 2023

Cidara Therapeutics Announces Promising Interim Phase 2a Data Assessing the Safety and Efficacy of a Single Dose of CD388 in an Influenza Challenge Model

GlobeNewswire March 1, 2023

Cidara to Present at ESMO Targeted Anticancer Therapies Congress

GlobeNewswire February 28, 2023

Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire February 14, 2023